Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.

Yi-Zi ZhengJia-Ying LiLv-Wen NingNi Xie

Published in: Breast cancer (Dove Medical Press) (2022)

Our study suggests that TRIM58 is a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer. It may also help to identify candidate responders and determine treatment strategies.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
rectal cancer
sentinel lymph node
squamous cell carcinoma
radiation therapy
early stage
young adults